References
- Maschio M. Brain tumor-related epilepsy. Curr Neuropharmacol. 2012;10:124–133.
- Zohu XW, Wang X, Yang Y, et al. Biomarkers related with seizure risk in glioma patients: a systematic review. Clin Neurol Neurosurg. 2016;151:113–119.
- Stockhammer F, Misch M, Helms HJ, et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. 2012;21:194–197.
- Rudà R, Bello L, Duffau H, et al. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 2012;14:iv55–iv64.
- Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia. 2013;54:97–104.
- Fycompa. Summary of product characteristics. [accessed 2017 Jun 21]; Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/002434/WC500130815.pdf
- Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481–1489.
- Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56:12–27.
- Rösche J, Piek J, Hildebrandt G, et al. Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation. Fortschr Neurol Psychiatr. 2015;83:286–289. (5):
- Vecht C. Duran-Peña, A, Houillier C, Durand T, Capelle L, Huberfeld G. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. J Neurooncol. 2017;133:603–607. doi: 10.1007/s11060-017-2473-1
- Marcus HJ1, Carpenter KL, Price SJ, et al. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol. 2010;97:11–23.
- Yuen TI, Morokoff AP, Bjorksten A, et al. Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology. 2012;79:883–889.
- Cunningham M, Jayasekera B, Da Silva B, et al. Targeting elevated glutamate in tumor-associated seizures. Abstract 2.368 presented at the American Epilepsy Society Annual Meeting 2016, Houston.
- Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol. 2009;11:260–273.
- de Groot JF, Piao Y, Lu L, et al. Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol. 2008;88:121–133.
- Trinka E, Steinhoff BJ, Nikanorova M, et al. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol Scand. 2016;133:160–172.
- Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v4.0. [accessed 2016 Nov 14]. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc/htm